1. Huffman J, Kossoff EH. State of the ketogenic diet(s) in epilepsy. Curr Neurol Neurosci Rep 2006; 6: 332–340.

1. Huffman JKossoff EH. State of the ketogenic diet(s) in epilepsy. Curr Neurol Neurosci Rep 2006; 6: 332–340.)| false
• Search Google Scholar
• Export Citation

2. Liu YM, Wang HS. Medium-chain triglyceride ketogenic diet, an effective treatment for drug-resistant epilepsy and a comparison with other ketogenic diets. Biomed J 2013; 36: 9–15.

2. Liu YMWang HS. Medium-chain triglyceride ketogenic diet, an effective treatment for drug-resistant epilepsy and a comparison with other ketogenic diets. Biomed J 2013; 36: 9–15.)| false
• Search Google Scholar
• Export Citation

3. Tagliabue A, Bertoli S, Trentani C, et al. Effects of the ketogenic diet on nutritional status, resting energy expenditure, and substrate oxidation in patients with medically refractory epilepsy: a 6-month prospective observational study. Clin Nutr 2012; 31: 246–249.

3. Tagliabue ABertoli STrentani C, et al. Effects of the ketogenic diet on nutritional status, resting energy expenditure, and substrate oxidation in patients with medically refractory epilepsy: a 6-month prospective observational study. Clin Nutr 2012; 31: 246–249.)| false
• Search Google Scholar
• Export Citation

4. Cunnane SC, Musa K, Ryan MA, et al. Potential role of polyunsaturates in seizure protection achieved with the ketogenic diet. Prostaglandins Leukot Essent Fatty Acids 2002; 67: 131–135.

4. Cunnane SCMusa KRyan MA, et al. Potential role of polyunsaturates in seizure protection achieved with the ketogenic diet. Prostaglandins Leukot Essent Fatty Acids 2002; 67: 131–135.)| false
• Search Google Scholar
• Export Citation

5. Cullingford TE. The ketogenic diet; fatty acids, fatty acid-activated receptors and neurological disorders. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 253–264.

5. Cullingford TE. The ketogenic diet; fatty acids, fatty acid-activated receptors and neurological disorders. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 253–264.)| false
• Search Google Scholar
• Export Citation

6. Eagles DA. Design of dietary treatment: humans versus rodents. Epilepsia 2008; 49 (suppl 8): 61–63.

6. Eagles DA. Design of dietary treatment: humans versus rodents. Epilepsia 2008; 49 (suppl 8): 61–63.)| false
• Search Google Scholar
• Export Citation

7. Crandall LA. A comparison of ketosis in man and dog. J Biol Chem 1941; 138: 123–128.

7. Crandall LA. A comparison of ketosis in man and dog. J Biol Chem 1941; 138: 123–128.)| false
• Search Google Scholar
• Export Citation

8. de Bruijne JJ, van den Brom WE. The effect of long-term fasting on ketone body metabolism in the dog. Comp Biochem Physiol B 1986; 83: 391–395.

8. de Bruijne JJvan den Brom WE. The effect of long-term fasting on ketone body metabolism in the dog. Comp Biochem Physiol B 1986; 83: 391–395.)| false
• Search Google Scholar
• Export Citation

9. Puchowicz MA, Smith CL, Bomont C, et al. Dog model of therapeutic ketosis induced by oral administration of R, S-1, 3-butanediol diacetoacetate. J Nutr Biochem 2000; 11: 281–287.

9. Puchowicz MASmith CLBomont C, et al. Dog model of therapeutic ketosis induced by oral administration of R, S-1, 3-butanediol diacetoacetate. J Nutr Biochem 2000; 11: 281–287.)| false
• Search Google Scholar
• Export Citation

10. Bergqvist AG, Schall JI, Stallings VA, et al. Progressive bone mineral content loss in children with intractable epilepsy treated with the ketogenic diet. Am J Clin Nutr 2008; 88: 1678–1684.

10. Bergqvist AGSchall JIStallings VA, et al. Progressive bone mineral content loss in children with intractable epilepsy treated with the ketogenic diet. Am J Clin Nutr 2008; 88: 1678–1684.)| false
• Search Google Scholar
• Export Citation

11. Christodoulides SS, Neal EG, Fitzsimmons G, et al. The effect of the classical and medium chain triglyceride ketogenic diet on vitamin and mineral levels. J Hum Nutr Diet 2012; 25: 16–26.

11. Christodoulides SSNeal EGFitzsimmons G, et al. The effect of the classical and medium chain triglyceride ketogenic diet on vitamin and mineral levels. J Hum Nutr Diet 2012; 25: 16–26.)| false
• Search Google Scholar
• Export Citation

12. Kang HC, Chung DE, Kim DW, et al. Early- and late-onset complications of the ketogenic diet for intractable epilepsy. Epilepsia 2004; 45: 1116–1123.

12. Kang HCChung DEKim DW, et al. Early- and late-onset complications of the ketogenic diet for intractable epilepsy. Epilepsia 2004; 45: 1116–1123.)| false
• Search Google Scholar
• Export Citation

13. Yuasa M, Matsui T, Ando S, et al. Consumption of a low-carbohydrate and high-fat diet (the ketogenic diet) exaggerates biotin deficiency in mice. Nutrition 2013; 29: 1266–1270.

13. Yuasa MMatsui TAndo S, et al. Consumption of a low-carbohydrate and high-fat diet (the ketogenic diet) exaggerates biotin deficiency in mice. Nutrition 2013; 29: 1266–1270.)| false
• Search Google Scholar
• Export Citation

14. National Research Council Ad Hoc Committee on Dog and Cat Nutrition. Nutrient requirements and dietary nutrient concentration. In: Nutrient requirements of dogs and cats. Washington, DC: National Academy Press, 2006; 354–370.

14. National Research Council Ad Hoc Committee on Dog and Cat Nutrition. Nutrient requirements and dietary nutrient concentration. In: Nutrient requirements of dogs and cats. Washington, DC: National Academy Press, 2006; 354–370.)| false
• Search Google Scholar
• Export Citation

15. Govendir M, Perkins M, Malik R. Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent. Aust Vet J 2005; 83: 602–608.

15. Govendir MPerkins MMalik R. Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent. Aust Vet J 2005; 83: 602–608.)| false
• Search Google Scholar
• Export Citation

16. Kluger EK, Malik R, Ilkin WJ, et al. Serum triglyceride concentration in dogs with epilepsy treated with phenobarbital or with phenobarbital and bromide. J Am Vet Med Assoc 2008; 233: 1270–1277.

16. Kluger EKMalik RIlkin WJ, et al. Serum triglyceride concentration in dogs with epilepsy treated with phenobarbital or with phenobarbital and bromide. J Am Vet Med Assoc 2008; 233: 1270–1277.)| false
• Search Google Scholar
• Export Citation

17. Hess RS, Kass PH, Shofer FS, et al. Evaluation of risk factors for fatal acute pancreatitis in dogs. J Am Vet Med Assoc 1999; 214: 46–51.

17. Hess RSKass PHShofer FS, et al. Evaluation of risk factors for fatal acute pancreatitis in dogs. J Am Vet Med Assoc 1999; 214: 46–51.)| false
• Search Google Scholar
• Export Citation

18. Gaskill CL, Cribb AE. Pancreatitis associated with potassium bromide/phenobarbital combination therapy in epileptic dogs. Can Vet J 2000; 41: 555–558.

18. Gaskill CLCribb AE. Pancreatitis associated with potassium bromide/phenobarbital combination therapy in epileptic dogs. Can Vet J 2000; 41: 555–558.)| false
• Search Google Scholar
• Export Citation

19. Stenier JM, Xenoulis PG, Anderson JA, et al. Serum pancreatic lipase immunoreactivity concentrations in dogs treated with potassium bromide and/or phenobarbital. Vet Ther 2008; 9: 37–44.

19. Stenier JMXenoulis PGAnderson JA, et al. Serum pancreatic lipase immunoreactivity concentrations in dogs treated with potassium bromide and/or phenobarbital. Vet Ther 2008; 9: 37–44.)| false
• Search Google Scholar
• Export Citation

20. Hess RS, Saunders HM, Van Winkle TJ, et al. Clinical, clinic-pathologic, radiographic, and ultrasonographic abnormalities in dogs with fatal acute pancreatitis: 70 cases (1986–1995). J Am Vet Med Assoc 1998; 213: 665–670.

20. Hess RSSaunders HMVan Winkle TJ, et al. Clinical, clinic-pathologic, radiographic, and ultrasonographic abnormalities in dogs with fatal acute pancreatitis: 70 cases (1986–1995). J Am Vet Med Assoc 1998; 213: 665–670.)| false
• Search Google Scholar
• Export Citation

21. Maguire PJ, Fettman MJ, O'Smith MO, et al. Effects of diet on pharmacokinetics of phenobarbital in healthy dogs. J Am Vet Med Assoc 2000; 217: 847–852.

21. Maguire PJFettman MJO'Smith MO, et al. Effects of diet on pharmacokinetics of phenobarbital in healthy dogs. J Am Vet Med Assoc 2000; 217: 847–852.)| false
• Search Google Scholar
• Export Citation

22. Apovian CM. The clinical and economic consequences of obesity. Am J Manag Care 2013; 19 (suppl 11): s219–s228.

22. Apovian CM. The clinical and economic consequences of obesity. Am J Manag Care 2013; 19 (suppl 11): s219–s228.)| false
• Search Google Scholar
• Export Citation

23. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49: 71–87.

23. Hanley MJAbernethy DRGreenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49: 71–87.)| false
• Search Google Scholar
• Export Citation

24. Wilkes L, Danziger LH, Rodvold KA. Phenobarbital pharmacokinetics in obesity. A case report. Clin Pharmacokinet 1992; 22: 481–484.

24. Wilkes LDanziger LHRodvold KA. Phenobarbital pharmacokinetics in obesity. A case report. Clin Pharmacokinet 1992; 22: 481–484.)| false
• Search Google Scholar
• Export Citation

25. Wuerzner G, Bochud M, Giusti V, et al. Measurement of glomerular filtration rate in obese patients: pitfalls and potential consequences on drug therapy. Obes Facts 2011; 4: 238–243.

25. Wuerzner GBochud MGiusti V, et al. Measurement of glomerular filtration rate in obese patients: pitfalls and potential consequences on drug therapy. Obes Facts 2011; 4: 238–243.)| false
• Search Google Scholar
• Export Citation

26. Wright C, Downing J, Mungall D, et al. Clinical pharmacology and pharmacokinetics of levetiracetam. Front Neurol 2013; 4: 1–6.

26. Wright CDowning JMungall D, et al. Clinical pharmacology and pharmacokinetics of levetiracetam. Front Neurol 2013; 4: 1–6.)| false
• Search Google Scholar
• Export Citation

27. Brodie MJ, Ben-Menachem E, Chouette I, et al. Zonisamide: its pharmacology, efficacy and safety in clinical trials. Acta Neurol Scand Suppl 2012; 194: 19–28.

27. Brodie MJBen-Menachem EChouette I, et al. Zonisamide: its pharmacology, efficacy and safety in clinical trials. Acta Neurol Scand Suppl 2012; 194: 19–28.)| false
• Search Google Scholar
• Export Citation

28. Kealy RD, Lawler DF, Ballam JM, et al. Effects of diet restriction on life span and age-related changes in dogs. J Am Vet Med Assoc 2002; 220: 1315–1320.

28. Kealy RDLawler DFBallam JM, et al. Effects of diet restriction on life span and age-related changes in dogs. J Am Vet Med Assoc 2002; 220: 1315–1320.)| false
• Search Google Scholar
• Export Citation

29. Fukunaga K, Saito M, Muto M, et al. Effects of urine pH modification on pharmacokinetics of phenobarbital in healthy dogs. J Vet Pharmacol Ther 2008; 31: 431–436.

29. Fukunaga KSaito MMuto M, et al. Effects of urine pH modification on pharmacokinetics of phenobarbital in healthy dogs. J Vet Pharmacol Ther 2008; 31: 431–436.)| false
• Search Google Scholar
• Export Citation

30. Kielb S, Koo HP, Bloom DA, et al. Nephrolithiasis associated with the ketogenic diet. J Urol 2000; 164: 464–466.

30. Kielb SKoo HPBloom DA, et al. Nephrolithiasis associated with the ketogenic diet. J Urol 2000; 164: 464–466.)| false
• Search Google Scholar
• Export Citation

31. Vernau KM, LeCouteur RA. Anticonvulsant drugs. In: Maddison JE, Page SW, Church DB, eds. Small animal clinical pharmacology. 2nd ed. Philadelphia: Elsevier Ltd, 2008; 367–379.

31. Vernau KMLeCouteur RA. Anticonvulsant drugs. In: Maddison JEPage SWChurch DB, eds. Small animal clinical pharmacology. 2nd ed. Philadelphia: Elsevier Ltd, 2008; 367–379.)| false
• Search Google Scholar
• Export Citation

32. Chandler K. Treatment and monitoring of epilepsy in dogs. In Pract 2011; 33: 98–104.

32. Chandler K. Treatment and monitoring of epilepsy in dogs. In Pract 2011; 33: 98–104.)| false
• Search Google Scholar
• Export Citation

33. Shaw N, Trepanier LA, Center SA, et al. High dietary chloride content associated with loss of therapeutic serum bromide concentrations in an epileptic dog. J Am Vet Med Assoc 1996; 208: 234–236.

33. Shaw NTrepanier LACenter SA, et al. High dietary chloride content associated with loss of therapeutic serum bromide concentrations in an epileptic dog. J Am Vet Med Assoc 1996; 208: 234–236.)| false
• Search Google Scholar
• Export Citation

34. Trepanier LA, Babish JG. Effect of dietary chloride content on the elimination of bromide by dogs. Res Vet Sci 1995; 58: 252–255.

34. Trepanier LABabish JG. Effect of dietary chloride content on the elimination of bromide by dogs. Res Vet Sci 1995; 58: 252–255.)| false
• Search Google Scholar
• Export Citation

35. Baird-Heinz HE, Van Schoick AL, Pelsor FR, et al. A systematic review of the safety of potassium bromide in dogs. J Am Vet Med Assoc 2012; 240: 705–715.

35. Baird-Heinz HEVan Schoick ALPelsor FR, et al. A systematic review of the safety of potassium bromide in dogs. J Am Vet Med Assoc 2012; 240: 705–715.)| false
• Search Google Scholar
• Export Citation

36. Trepanier LA. Use of bromide as an anticonvulsant for dogs with epilepsy. J Am Vet Med Assoc 1995; 207: 163–166.

36. Trepanier LA. Use of bromide as an anticonvulsant for dogs with epilepsy. J Am Vet Med Assoc 1995; 207: 163–166.)| false
• Search Google Scholar
• Export Citation

37. Rosser EJ. Diagnosis of food allergy in dogs. J Am Vet Med Assoc 1995; 203: 259–262.

37. Rosser EJ. Diagnosis of food allergy in dogs. J Am Vet Med Assoc 1995; 203: 259–262.)| false
• Search Google Scholar
• Export Citation

38. Frediani T, Pelliccia A, Aprile A, et al. Partial idiopathic epilepsy: recovery after allergen-free diet. Pediatr Med Chir 2004; 26: 196–197.

38. Frediani TPelliccia AAprile A, et al. Partial idiopathic epilepsy: recovery after allergen-free diet. Pediatr Med Chir 2004; 26: 196–197.)| false
• Search Google Scholar
• Export Citation

39. Strine TW, Kobau R, Chapman DP. Psychological distress, comorbidities, and health behaviors among U.S. adults with seizures: results from the 2002 National Health Interview Survey. Epilepsia 2005; 46: 1133–1139.

39. Strine TWKobau RChapman DP. Psychological distress, comorbidities, and health behaviors among U.S. adults with seizures: results from the 2002 National Health Interview Survey. Epilepsia 2005; 46: 1133–1139.)| false
• Search Google Scholar
• Export Citation

40. Silverberg JI, Joks R, Durkin HG. Allergic disease is associated with epilepsy in childhood: a US population-based study. Allergy 2014; 69: 95–103.

40. Silverberg JIJoks RDurkin HG. Allergic disease is associated with epilepsy in childhood: a US population-based study. Allergy 2014; 69: 95–103.)| false
• Search Google Scholar
• Export Citation

41. Anderson GJ, Conner WE, Corliss JD. Docosahexaenoic acid is the preferred dietary n-3 fatty acid for the development of the brain, retina. Pediatr Res 1990; 27: 89–97.

41. Anderson GJConner WECorliss JD. Docosahexaenoic acid is the preferred dietary n-3 fatty acid for the development of the brain, retina. Pediatr Res 1990; 27: 89–97.)| false
• Search Google Scholar
• Export Citation

42. Ferrari D, Cysneiros RM, Scorza CA, et al. Neuroprotective activity of omega-3 fatty acids against epilepsy-induced hippocampal damage: quantification with immunohistochemical for calcium-binding protein. Epilepsy Behav 2008; 13: 36–42.

42. Ferrari DCysneiros RMScorza CA, et al. Neuroprotective activity of omega-3 fatty acids against epilepsy-induced hippocampal damage: quantification with immunohistochemical for calcium-binding protein. Epilepsy Behav 2008; 13: 36–42.)| false
• Search Google Scholar
• Export Citation

43. Bauer JE. Therapeutic use of fish oils in companion animals. J Am Vet Med Assoc 2011; 239: 1441–1451.

43. Bauer JE. Therapeutic use of fish oils in companion animals. J Am Vet Med Assoc 2011; 239: 1441–1451.)| false
• Search Google Scholar
• Export Citation

44. Bellissimo MI, Amado D, Abdalla DS, et al. Superoxide dismutase, glutathione peroxidase activities and the hydroperoxide concentration are modified in the hippocampus of epileptic rats. Epilepsy Res 2001; 46: 121–128.

44. Bellissimo MIAmado DAbdalla DS, et al. Superoxide dismutase, glutathione peroxidase activities and the hydroperoxide concentration are modified in the hippocampus of epileptic rats. Epilepsy Res 2001; 46: 121–128.)| false
• Search Google Scholar
• Export Citation

45. Naffah-Mazzacoratti MG, Bellíssimo MI, Cavalheiro EA. Profile of prostaglandin levels in the rat hippocampus in pilocarpine model of epilepsy. Neurochem Int 1995; 27: 461–466.

45. Naffah-Mazzacoratti MGBellíssimo MICavalheiro EA. Profile of prostaglandin levels in the rat hippocampus in pilocarpine model of epilepsy. Neurochem Int 1995; 27: 461–466.)| false
• Search Google Scholar
• Export Citation

46. Scorza FA, Cavalheiro EA, Arido RM, et al. Positive impact of omega-3 fatty acid supplementation in a dog with drug-resistant epilepsy: a case study. Epilepsy Behav 2009; 15: 527–528.

46. Scorza FACavalheiro EAArido RM, et al. Positive impact of omega-3 fatty acid supplementation in a dog with drug-resistant epilepsy: a case study. Epilepsy Behav 2009; 15: 527–528.)| false
• Search Google Scholar
• Export Citation

47. Matthews H, Grander N, Wood J, et al. Effects of essential fatty acid supplementation in dogs with idiopathic epilepsy: a clinical trial. Vet J 2012; 191: 396–398.

47. Matthews HGrander NWood J, et al. Effects of essential fatty acid supplementation in dogs with idiopathic epilepsy: a clinical trial. Vet J 2012; 191: 396–398.)| false
• Search Google Scholar
• Export Citation

48. Bauer JE. Evaluation and dietary consideration in idiopathic hyperlipidemia in dogs. J Am Vet Med Assoc 1995; 206: 1684–1688.

48. Bauer JE. Evaluation and dietary consideration in idiopathic hyperlipidemia in dogs. J Am Vet Med Assoc 1995; 206: 1684–1688.)| false
• Search Google Scholar
• Export Citation

49. Oja SS, Saransaari P. Taurine and epilepsy. Epilepsy Res 2013; 104: 187–194.

49. Oja SSSaransaari P. Taurine and epilepsy. Epilepsy Res 2013; 104: 187–194.)| false
• Search Google Scholar
• Export Citation

50. Ripps H, Shen W. Taurine: a “very essential” amino acid. Mol Vision 2010; 18: 2673–2686.

50. Ripps HShen W. Taurine: a “very essential” amino acid. Mol Vision 2010; 18: 2673–2686.)| false
• Search Google Scholar
• Export Citation

51. Tanizawa K, Mizuno T, Ueda K, et al. Taurine treatment for spontaneous epilepsy in the cat. Jpn J Vet Sci 1986; 48: 1041–1043.

51. Tanizawa KMizuno TUeda K, et al. Taurine treatment for spontaneous epilepsy in the cat. Jpn J Vet Sci 1986; 48: 1041–1043.)| false
• Search Google Scholar
• Export Citation

52. van Gelder NM, Koyama I, Jasper HH. Taurine treatment of spontaneous chronic epilepsy in a cat. Epilepsia 1977; 18: 45–54.

52. van Gelder NMKoyama IJasper HH. Taurine treatment of spontaneous chronic epilepsy in a cat. Epilepsia 1977; 18: 45–54.)| false
• Search Google Scholar
• Export Citation

53. van Gelder NM, Edmonds HL, Hegreberg GA, et al. Amino acid changes in a genetic strain of epileptic Beagle dogs. J Neurochem 1980; 35: 1087–1091.

53. van Gelder NMEdmonds HLHegreberg GA, et al. Amino acid changes in a genetic strain of epileptic Beagle dogs. J Neurochem 1980; 35: 1087–1091.)| false
• Search Google Scholar
• Export Citation

54. Volk HA, Davies E. Trial of a novel diet for epilepsy in dogs. Vet Rec 2013; 172: 319–320.

54. Volk HADavies E. Trial of a novel diet for epilepsy in dogs. Vet Rec 2013; 172: 319–320.)| false
• Search Google Scholar
• Export Citation